M. Kulyk & Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
M. Kulyk & Associates's NVO Position: Q3 2026 in Review
M. Kulyk & Associates reduced its Novo Nordisk (NVO) stake by 3.2% in Q3 2026, selling an estimated $139K and leaving 90,386 shares worth $3.43M. The position accounts for 0.57% of the portfolio, ranked #43.
M. Kulyk & Associates first reported a position in NVO in Q4 2023 and has held it in 12 quarters since. The position peaked at $7.75M in Q4 2025. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- M. Kulyk & Associates held 90,386 shares of Novo Nordisk worth $3.43M as of Q3 2026.
- M. Kulyk & Associates sold 3,014 Novo Nordisk shares in Q3 2026, an estimated $139K.
- Novo Nordisk made up 0.57% of M. Kulyk & Associates's portfolio in Q3 2026, its #43 holding.
- M. Kulyk & Associates first reported a position in Novo Nordisk in Q4 2023 and has held it in 12 quarters since.
- M. Kulyk & Associates's Novo Nordisk position peaked at $7.75M in Q4 2025.
- 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on M. Kulyk & Associates's 13F filing for Q3 2026, filed 10 Nov 2026.